Durvalumab vs Montelukast

## Durvalumab vs Montelukast: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Montelukast**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Montelukast**: Selective leukotriene D4 receptor antagonist.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Montelukast — 2.7-5.5 hours.

## Chemical Properties

**Molecular Formula**: Durvalumab — N/A; Montelukast — C35H36ClNO3S.

**Molecular Weight**: Durvalumab — N/A; Montelukast — 586.1800 g/mol.

**Type**: Durvalumab — Antibody; Montelukast — Small molecule.